FORM 6-K
 
 
 
SECURITIES AND EXCHANGE COMMISSION

 
Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

 
the Securities Exchange Act of 1934
 
 
 
For period ending 22 May 2017
 
 
GlaxoSmithKline plc
 
(Name of registrant)
 
 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
 
(Address of principal executive offices)

 
 
Indicate by check mark whether the registrant files or
 
will file annual reports under cover Form 20-F or Form 40-F

 
 
Form 20-F x     Form 40-F

 
--

 
 
Indicate by check mark whether the registrant by furnishing the
 
information contained in this Form is also thereby furnishing the
 
information to the Commission pursuant to Rule 12g3-2(b) under the
 
Securities Exchange Act of 1934.

 
 
 
Yes      No x
 
 
GlaxoSmithKline plc (the 'Company')
 
Transaction notification
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr R G Connor
b)
Position/status
President, Global Manufacturing & Supply
c)
Initial notification/
amendment
Initial Notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
b)
Nature of the transaction
The sale of 16,065 Ordinary Shares on 19 May 2017 at a price of £16.4227.
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
£16.4227
16,065
 
 
 
d)
Aggregated information
n/a (single transaction)
 
Aggregated  volume Price
 
e)
Date of the transaction
 
f)
Place of the transaction
 
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mrs D Connor
b)
Position/status
PCA of Mr R G Connor (President, Global Manufacturing & Supply)
c)
Initial notification/
amendment
Initial Notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
b)
Nature of the transaction
The sale of 7,435 Ordinary Shares on 19 May 2017 at a price of £16.4153.
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
£16.4153
7,435
 
 
 
d)
Aggregated information
n/a (single transaction)
Aggregated volume Price
 
e)
Date of the transaction
2017-05-19
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
SIGNATURES
 
 
 
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

 
 
GlaxoSmithKline plc
 
 
(Registrant)
 
 
 
Date: May 22, 2017 
 
 
 
 
 
By: VICTORIA WHYTE--------------------------
 
 
 
 
Victoria Whyte
 
 
Authorised Signatory for and on
 
 
behalf of GlaxoSmithKline plc